Liver injury associated with the beta-interferons for MS: a comparison between the three products.

Joel Oger, Helen L Tremlett, Eric M Yoshida

Journal: Neurology 2005;62(4):628-31

PMID: 14981183

Abstract

A population-based retrospective chart review of the biochemical liver tests of 844 patients with multiple sclerosis prescribed a beta-interferon (IFNbeta) product in British Columbia, Canada was performed between 1995 and 2001. Overall, 36.9% (243/659) of patients developed new elevations of alanine aminotransferase. All the IFNbetas caused elevated aminotransferase levels compared with pretreatment levels (p < 0.005) and were higher than reported in clinical trials. Their relative effect on aminotransferases can be approximated as IFNbeta-1b(subcutaneous [SC]) = IFNbeta-1a(SC) > IFNbeta-1a(IM).

Address: Department of Medicine, Division of Neurology, Vancouver Hospital & Health Sciences Center, University of British Columbia, Vancouver, BC, Canada. [email protected]

DOI: 10.1212/wnl.62.4.628

Link outs

Free resources

Medical:

https://medlineplus.gov/multiplesclerosis.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Subscription / membership required

Full Text Sources:

MeSH Terms: Adult, Alanine Transaminase, Aspartate Aminotransferases, Biomarkers, British Columbia, Chemical and Drug Induced Liver Injury, Chronic, Drug Monitoring, Female, Follow-Up Studies, Humans, Injections, Intramuscular, Injections, Subcutaneous, Interferon beta-1a, Interferon beta-1b, Interferon-beta, Male, Middle Aged, Multiple Sclerosis, Retrospective Studies, Risk Factors